Pfizer is licensing the technology behind OXECTA, called AVERSION, from Acura Pharmaceuticals.
OXECTA is indicated for the management of acute and chronic pain that is moderate to severe and where use of opioids is appropriate.
Read the Pfizer release on oxycodone.
Related Articles on Opioids for Pain Management:
Study: Prescription Drug-Related Harm Primarily Involved Opioids
Opioids Market Headed for Steeper Growth
Army Grants $5.6M to Research Sublingual Opioid for Pain
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
